Histone deacetylase 1, 2, 6 and acetylated histone H4 in diffuse large B-cell lymphomas
Here, we present an immunohistochemical study on the expression of three HDACs (HDAC1, HDAC2, and HDAC6) together with acetylated histone H4 in pre-treatment, clinical samples from 31 primary nodal DLBCL patients. Expression was characterized as low, moderate, or high expression based on the number of positively stained malignant B-cells, and the staining intensity. The expression profiles were correlated with the DLBCL subtype, i.e. germinal center B-cell (GCB) (n=11) vs. non-GCB (n=20) and with overall survival.
The results showed moderate to high expression of HDAC1, HDAC2, HDAC6, and acetylated H4 in the malignant B-cells of 80.6%, 90.4%, 71.0%, and 74.2% of the samples, respectively. When looking at the entire cohort, HDAC2 was expressed more abundantly than HDAC6 (p=0.0006). The expression profiles of the remaining compounds were similar (p>0.05) and no differences were detected between DLBCL GCB vs. non-GCB subtype. In terms of survival, moderate to strong HDAC6 expression was significantly correlated with a favourable outcome (p=0.016) compared to low expression. Expression levels of HDAC1, HDAC2, and acetylated H4 did not correlate with survival (>0.05).
In conclusion, it is shown that HDAC1, HDAC2, HDAC6, and acetylated H4 are overexpressed in DLBCL, and that HDAC6 may be an important prognostic marker in this disease.
Document Type: Abstract
Affiliations: 1: Finsenlaboratoriet, Københavns Biocenter, Rigshospitalet, Ole Maaløes Vej 5, 2200 København N 2: Eksperimentel Patologienhed, Patologiafdelingen, Rigshospitalet, Ole Maaløes vej 5, 2200 København N
Publication date: May 1, 2008